- Stocks
- Pharma & Healthcare
- Shanmuga Hospit
Shanmuga Hospit share price
NSE: SHANMUGAPharma & HealthcareMedical Care Facilities
Shanmuga Hospit at a glance
With a market capitalisation of ₹48 Cr, it ranks 3100th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Care Facilities.
Its return on equity was 9.9% in FY26. Promoters held 72.06% of the company as of 31 Mar 2026.
Key numbers
- Market cap
- ₹48 CrRank 3100 on NSE
- Price to book
- 1.13×FY26
- ROE
- 9.9%FY26
- ROCE
- 12.8%FY26
- Debt to equity
- 0.16FY26
- Net profit margin
- 8.9%FY26
- Book value / share
- ₹31.22FY26
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Shanmuga Hospit financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹8 Cr | ₹13 Cr | ₹13 Cr | ₹14 Cr | ₹17 Cr | ₹17 Cr |
| Operating profit | −₹1 Cr | ₹2 Cr | ₹1 Cr | ₹5 Cr | ₹6 Cr | ₹4 Cr |
| Net profit | −₹1 Cr | ₹1 Cr | ₹4 Cr | ₹3 Cr | ₹4 Cr | ₹3 Cr |
| EPS (₹) | −₹1.00 | ₹1.00 | ₹3.00 | ₹3.00 | ₹3.00 | ₹2.00 |
| Total debt | ₹0 Cr | ₹0 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr |
| Shareholders' equity | ₹0 Cr | ₹7 Cr | ₹12 Cr | ₹17 Cr | ₹40 Cr | ₹43 Cr |
Shanmuga Hospit shareholding pattern
| Holder | 18 Feb 2025 | 31 Mar 2025 | 30 Sep 2025 | 31 Mar 2026 |
|---|---|---|---|---|
| Promoters | 71.95% | 72.11% | 72.06% | 72.06% |
| Non-institutions | 28.05% | 27.69% | 27.94% | 27.94% |
Shanmuga Hospit vs peers
The listed Pharma & Healthcare companies nearest to Shanmuga Hospit by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| SHREEPACShree Pacetroni | — | — | — | ₹50 Cr | — | — |
| BIOFILCHEMBiofil Chemicals & Pharmaceuticals | ₹30.00 | +2.15% | −27.3% | ₹49 Cr | 17.5 | — |
| SHANMUGAShanmuga Hospit | — | — | — | ₹48 Cr | — | — |
| MANGALAMMangalam Drugs And Organics | ₹29.66 | −3.07% | −58.5% | ₹47 Cr | — | — |
| AMKAYAmkay Products | — | — | — | ₹46 Cr | — | — |
| SHELTERShelter Pharma | — | — | — | ₹46 Cr | — | — |
| VISTAPHVista Pharma | — | — | — | ₹45 Cr | — | — |
Ask anything about Shanmuga Hospit
Pivot answers on the live chart with evidence you can check, and tests strategies against SHANMUGA's own history. Try: “Why has SHANMUGA moved over the last three months?” · “Backtest a 50-day moving-average crossover on SHANMUGA over five years” · “Compare SHANMUGA with SHREEPAC on margins and valuation”
Frequently asked questions about Shanmuga Hospit
What is the market cap of Shanmuga Hospit?
Shanmuga Hospit's market capitalisation is ₹48 Cr (₹48 Cr) at the 22 Oct 2026 close, ranking 3100th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Shanmuga Hospit?
Return on equity was 9.9% in FY26 and return on capital employed was 12.8% in FY26 (standalone figures).
Is Shanmuga Hospit a debt-free company?
No. Shanmuga Hospit's debt-to-equity ratio was 0.16 in FY26, with total debt of ₹4 Cr.
What is the shareholding pattern of Shanmuga Hospit?
As of 31 Mar 2026: promoters 72.06%, non-institutions 27.94%.
Who are Shanmuga Hospit's competitors?
The listed Pharma & Healthcare companies closest to Shanmuga Hospit by market cap are Shree Pacetroni, Biofil Chemicals & Pharmaceuticals, Mangalam Drugs And Organics, Amkay Products, Shelter Pharma and Vista Pharma.
Is Shanmuga Hospit a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Shanmuga Hospit's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SHANMUGA against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with S · all NSE stocks · this page as text